Company: RGBP
Filing Date: 2025-08-11
Form Type: 10-Q
Source: 0001641172-25-022884
Chunk: 27

Company: Regen BioPharma Inc
Filing Date: 2025-08-11
Form: 10-Q
Item: Part II, Item 2
Chunk 27
---
 and payable
on August 5, 2026.

The
Holder of this Note is entitled, at its option,, to convert all or any amount of the principal face amount of this Note and interest
then outstanding into shares of the Company’s common stock (the “ Common Stock”) at a price (“ Conversion Price”)
for each share of Common Stock equal to 60% of the lowest trading price of the Common Stock as reported on the OTC Markets on which the
Company’s shares are then traded or any exchange up-on which the Common Stock may be traded in the future (the “ Exchange”),
for the twenty prior trading days ending on the latest complete Trading Day prior to the Conversion Date.

The
Note was issued pursuant to Section 4(a) (2) of the Securities Act of 1933, as amended (the “ Act”). No underwriters were
retained to serve as placement agents for the sale. The Note sold directly through our management. No commission or other consideration
was paid in connection with the sale of the Note. There was no advertisement or general solicitation made in connection with this Offer
and Sale of the Note. A legend was placed on the Note that evidences the Note has not been registered under the Act and setting forth
or referring to the restrictions on transferability and sale of the Note and the shares into which the Note may be converted.

Item
6. Exhibit Index